Adrenocortical suppression and recovery after continuous hypnotic infusion: Etomidate versus its soft analogue cyclopropyl-methoxycarbonyl metomidate

Critical Care

Volumn 17, Issue 1, 2013, Pages

  Ge, Rile ^a   Pejo, Ervin ^a   Cotten, Joseph F ^a   Raines, Douglas E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; DEXAMETHASONE; ETOMIDATE; METOMIDATE;

ADRENAL CORTEX FUNCTION; ANESTHESIA LEVEL; ANIMAL EXPERIMENT; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; HYPNOSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 84873032897     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12494     Document Type: Article

References (33)

1. Godefroi EF, Janssen PA, Vandereycken CA, Vanheertum AH, Niemegeers CJ. Dl-1-(1-arylalkyl)imidazole-5-carboxylate esters. A novel type of hypnotic agent. J Med Chem 1965, 8:220-223. 10.1021/jm00326a017, 14332665.
2. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983, 1:1270.
3. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984, 39:973-981. 10.1111/j.1365-2044.1984.tb08885.x, 6496912.
4. Fry DE, Griffiths H. The inhibition by etomidate of the 11 beta-hydroxylation of cortisol. Clin Endocrinol (Oxf) 1984, 20:625-629.
5. den Brinker M, Joosten KF, Liem O, de Jong FH, Hop WC, Hazelzet JA, van Dijk M, Hokken-Koelega AC. Adrenal insufficiency in meningococcal sepsis: bioavailable cortisol levels and impact of interleukin-6 levels and intubation with etomidate on adrenal function and mortality. J Clin Endocrinol Metab 2005, 90:5110-5117. 10.1210/jc.2005-1107, 15985474.
6. Lipiner-Friedman D, Sprung CL, Laterre PF, Weiss Y, Goodman SV, Vogeser M, Briegel J, Keh D, Singer M, Moreno R, Bellissant E, Annane D. Adrenal function in sepsis: the retrospective Corticus cohort study. Crit Care Med 2007, 35:1012-1018. 10.1097/01.CCM.0000259465.92018.6E, 17334243.
7. Hildreth AN, Mejia VA, Maxwell RA, Smith PW, Dart BW, Barker DE. Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008, 65:573-579. 10.1097/TA.0b013e31818255e8, 18784570.
8. Cuthbertson BH, Sprung CL, Annane D, Chevret S, Garfield M, Goodman S, Laterre PF, Vincent JL, Freivogel K, Reinhart K, Singer M, Payen D, Weiss YG. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009, 35:1868-1876. 10.1007/s00134-009-1603-4, 19652948.
9. Chan CM, Mitchell AL, Shorr AF. Etomidate is associated with mortality and adrenal insufficiency in sepsis: a meta-analysis*. Crit Care Med 2012, 40:2945-2953. 10.1097/CCM.0b013e31825fec26, 22971586.
10. Asehnoune K, Mahe PJ, Seguin P, Jaber S, Jung B, Guitton C, Chatel-Josse N, Subileau A, Tellier AC, Masson F, Renard B, Malledant Y, Lejus C, Volteau C, Sebille V, Roquilly A. Etomidate increases susceptibility to pneumonia in trauma patients. Intensive Care Med 2012, 38:1673-1682. 10.1007/s00134-012-2619-8, 22777514.
11. Cotten JF, Husain SS, Forman SA, Miller KW, Kelly EW, Nguyen HH, Raines DE. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009, 111:240-249. 10.1097/ALN.0b013e3181ae63d1, 2739411, 19625798.
12. Ge RL, Pejo E, Haburcak M, Husain SS, Forman SA, Raines DE. Pharmacological studies of methoxycarbonyl etomidate's carboxylic acid metabolite. Anesth Analg 2012, 115:305-308. 10.1213/ANE.0b013e318239c6ca, 22052979.
13. Pejo E, Ge R, Banacos N, Cotten JF, Husain SS, Raines DE. Electroencephalographic recovery, hypnotic emergence, and the effects of metabolite following continuous infusions of a rapidly metabolized eomidate analog in rats. Anesthesiology 2012, 116:1057-1065. 10.1097/ALN.0b013e3182515403, 22417966.
14. Husain SS, Pejo E, Ge R, Raines DE. Modifying methoxycarbonyl etomidate inter-ester spacer optimizes in vitro metabolic stability and in vivo hypnotic potency and duration of action. Anesthesiology 2012, 117:1027-1036. 10.1097/ALN.0b013e31826d3bef, 22929736.
15. Ge R, Pejo E, Husain SS, Cotten JF, Raines DE. Electroencephalographic and hypnotic recoveries following brief and prolonged infusions of etomidate and optimized soft etomidate analogs. Anesthesiology 2012, 117:1037-1043. 10.1097/ALN.0b013e31826d3de2, 22929726.
16. de Jong FH, Mallios C, Jansen C, Scheck PA, Lamberts SW. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984, 59:1143-1147. 10.1210/jcem-59-6-1143, 6092411.
17. Fragen RJ, Shanks CA, Molteni A, Avram MJ. Effects of etomidate on hormonal responses to surgical stress. Anesthesiology 1984, 61:652-656. 10.1097/00000542-198412000-00004, 6095701.
18. Wagner RL, White PF. Etomidate inhibits adrenocortical function in surgical patients. Anesthesiology 1984, 61:647-651. 10.1097/00000542-198412000-00003, 6095700.
19. Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983, 287:1835-1837.
20. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999, 54:861-867. 10.1046/j.1365-2044.1999.01003.x, 10460557.
21. den Brinker M, Hokken-Koelega AC, Hazelzet JA, de Jong FH, Hop WC, Joosten KF. One single dose of etomidate negatively influences adrenocortical performance for at least 24 h in children with meningococcal sepsis. Intensive Care Med 2008, 34:163-168. 10.1007/s00134-007-0836-3, 2668631, 17710382.
22. Kulstad EB, Kalimullah EA, Tekwani KL, Courtney DM. Etomidate as an induction agent in septic patients: red flags or false alarms?. West J Emerg Med 2010, 11:161-172. 2908652, 20823967.
23. Tomlin SL, Jenkins A, Lieb WR, Franks NP. Stereoselective effects of etomidate optical isomers on gamma-aminobutyric acid type A receptors and animals. Anesthesiology 1998, 88:708-717. 10.1097/00000542-199803000-00022, 9523815.
24. Husain SS, Ziebell MR, Ruesch D, Hong F, Arevalo E, Kosterlitz JA, Olsen RW, Forman SA, Cohen JB, Miller KW. 2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels. J Med Chem 2003, 46:1257-1265. 10.1021/jm020465v, 12646036.
25. Roumen L, Sanders MP, Pieterse K, Hilbers PA, Plate R, Custers E, de Gooyer M, Smits JF, Beugels I, Emmen J, Ottenheijm HCJ, Leysen D, Hermans JJR. Construction of 3D models of the CYP11B family as a tool to predict ligand binding characteristics. J Comput Aided Mol Des 2007, 21:455-471. 10.1007/s10822-007-9128-9, 2039848, 17646925.
26. Cotten JF, Forman SA, Laha JK, Cuny GD, Husain SS, Miller KW, Nguyen HH, Kelly EW, Stewart D, Liu A, Raines DE. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010, 112:637-644. 10.1097/ALN.0b013e3181cf40ed, 2830733, 20179500.
27. Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology 2011, 114:695-707. 10.1097/ALN.0b013e3181ff72b5, 3108152, 21263301.
28. Calvo R, Carlos R, Erill S. Etomidate and plasma esterase activity in man and experimental animals. Pharmacology 1979, 18:294-298. 10.1159/000137268, 493334.
29. Quon CY, Mai K, Patil G. Species differences in the stereoselective hydrolysis of esmolol by blood esterases. Drug Metab Dispos 1988, 16:425-428.
30. Egan TD. Is anesthesiology going soft?: trends in fragile pharmacology. Anesthesiology 2009, 111:229-230. 10.1097/ALN.0b013e3181ae8460, 19625797.
31. Bodor N, Buchwald P. Soft drug design: general principles and recent applications. Med Res Rev 2000, 20:58-101. 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X, 10608921.
32. Sarafidis PA, Georgianos PI, Malindretos P, Liakopoulos V. Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents. Expert Opin Investig Drugs 2012, 21:1089-1106. 10.1517/13543784.2012.693477, 22667825.
33. Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg 2012, 115:274-283. 10.1213/ANE.0b013e31823f0c28, 22190555.